ArticleBrain : a journal of neurology2020
Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators.
Article in Brain : a journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine.Frontiers in immunology · 2021Pooled it
- The Imbalance Between Tumor Immunosurveillance and Tumor Immune Escape in Glioblastoma.Immunology and cell biology · 2026Review
- Whole-body TSPO-PET reveals stage-dependent disruption of systemic immune organ interactions in glioblastoma.European journal of nuclear medicine and molecular imaging · 2026Article
- Generation of Allogeneic CAR-T Circumvents Functional Deficits in Patient-Derived Autologous Product for Glioblastoma.International journal of cancer · 2026Article
- Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression in mice.Nature communications · 2026Article
- A novel murine model of LITT for glioblastoma reveals tumor reduction, BBB permeabilization, and drug delivery via ThermoDoxDrug delivery and translational research · 2026Article
- Circulating immune profiling reveals impaired monocyte states and trajectories driving immunosuppression in glioblastoma.Journal of neuroinflammation · 2026Article
- Reprogramming the immune orchestra for glioblastoma: oncolytic viruses and the B-cell connection.Cellular & molecular immunology · 2026Article
- Glioblastoma radiomics can delineate systemic immune activity states like blood abundance of T cell populations or transcription factors.Journal of neuroinflammation · 2026Article
- Peripheral vaccination-induced brain-resident memory CD8+ T cells durably protect mice against intracranial malignancy.The Journal of clinical investigation · 2026Article
- Oncolytic virus M1 reinvigorates CD8Cellular & molecular immunology · 2026Article
- Tumors located in the brain impair the frequency and phenotype of dendritic cells in blood and tumor.iScience · 2026Article
- Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy.Molecular therapy. Oncology · 2026Article
- Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy.Acta pharmaceutica Sinica. B · 2026Review
- Radiation immunodynamics: association of baseline and longitudinal cytokine levels during radiotherapy in glioblastoma with survival.Journal of neuro-oncology · 2026Article
- A characterisation of the immune cells in immunocompetent and immunodeficient mice with orthotopic brain tumors.Clinical & translational immunology · 2026Article
- Thymic regeneration and tumor immunotherapy.Frontiers in immunology · 2026Review
- Antigen-specific CD8 T cells are generated and reactivated in the bone marrow following viral brain infections and impact the bone marrow niche.bioRxiv : the preprint server for biology · 2025Article
- Plasma Extracellular Vesicles as Liquid Biopsies for Glioblastoma: Biomarkers, Subpopulation Enrichment, and Clinical Translation.International journal of molecular sciences · 2025Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 2 countries.
Funding
Abstract
Immunosuppression of unknown aetiology is a hallmark feature of glioblastoma and is characterized by decreased CD4 T-cell counts and downregulation of major histocompatibility complex class II expression on peripheral blood monocytes in patients. This immunosuppression is a critical barrier to the successful development of immunotherapies for glioblastoma. We recapitulated the immunosuppression observed in glioblastoma patients in the C57BL/6 mouse and investigated the aetiology of low CD4 T-cell counts. We determined that thymic involution was a hallmark feature of immunosuppression in three distinct models of brain cancer, including mice harbouring GL261 glioma, B16 melanoma, and in a spontaneous model of diffuse intrinsic pontine glioma. In addition to thymic involution, we determined that tumour growth in the brain induced significant splenic involution, reductions in peripheral T cells, reduced MHC II expression on blood leucocytes, and a modest increase in bone marrow resident CD4 T cells. Using parabiosis we report that thymic involution, declines in peripheral T-cell counts, and reduced major histocompatibility complex class II expression levels were mediated through circulating blood-derived factors. Conversely, T-cell sequestration in the bone marrow was not governed through circulating factors. Serum isolated from glioma-bearing mice potently inhibited proliferation and functions of T cells both in vitro and in vivo. Interestingly, the factor responsible for immunosuppression in serum is non-steroidal and of high molecular weight. Through further analysis of neurological disease models, we determined that the immunosuppression was not unique to cancer itself, but rather occurs in response to brain injury. Non-cancerous acute neurological insults also induced significant thymic involution and rendered serum immunosuppressive. Both thymic involution and serum-derived immunosuppression were reversible upon clearance of brain insults. These findings demonstrate that brain cancers cause multifaceted immunosuppression and pinpoint circulating factors as a target of intervention to restore immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.